Braggio, Esteban

Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma

Keats, J. J., Fonseca, R., Chesi, M., Schop, R., Baker, A., Chng, W.-J., Van Wier, S., Tiedemann, R., Shi, C.-X., Sebag, M., et al. (2007) · Cancer Cell

Multiple Myeloma Research and TreatmentsNF-κB Signaling Pathways

Cited by 983

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 607

Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma

Zavidij, O., Haradhvala, N. J., Mouhieddine, T. H., Sklavenitis-Pistofidis, R., Cai, S., Reidy, M., Rahmat, M., Flaifel, A., Ferland, B., Su, N. K., et al. (2020) · Nature Cancer

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 374

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

Kortüm, K. M., Mai, E. K., Hanafiah, N. H., Shi, C.-X., Zhu, Y.-X., Bruins, L., Barrio, S., Jedlowski, P., Merz, M., Xu, J., et al. (2016) · Blood

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 255

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma

Zhu, Y. X., Braggio, E., Shi, C.-X., Kortuem, K. M., Bruins, L. A., Schmidt, J. E., Chang, X.-B., Langlais, P., Luo, M., Jedlowski, P., et al. (2014) · Blood

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 213

MYC dysregulation in the progression of multiple myeloma

MMRF CoMMpass Network, Misund, K., Keane, N., Stein, C. K., Asmann, Y. W., Day, G., Welsh, S., Van Wier, S. A., Riggs, D. L., Ahmann, G., et al. (2020) · Leukemia

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 161

High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma

Miller, A., Asmann, Y., Cattaneo, L., Braggio, E., Keats, J., Auclair, D., Lonial, S., The MMRF CoMMpass Network, Russell, S. J., & Stewart, A. K. (2017) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsCancer Immunotherapy and Biomarkers

Cited by 145

The clinical significance of cereblon expression in multiple myeloma

Schuster, S. R., Kortuem, K. M., Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Ahmann, G., Kumar, S., Rajkumar, S. V., et al. (2014) · Leukemia Research

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 113

IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma

Barrio, S., Munawar, U., Zhu, Y. X., Giesen, N., Shi, C.-X., Viá, M. D., Sanchez, R., Bruins, L., Demler, T., Müller, N., et al. (2020) · Haematologica

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 67

Uncovering the biology of multiple myeloma among African Americans: A comprehensive genomics approach

Baker, A., Braggio, E., Jacobus, S., Jung, S., Larson, D., Therneau, T., Dispenzieri, A., Van Wier, S. A., Ahmann, G., Levy, J., et al. (2013) · Blood

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 66

Genomics define malignant transformation in myeloma precursor conditions

Maura, F., Bergsagel, P. L., Ziccheddu, B., Kumar, S., Maclachlan, K., Derkach, A., Garces, J.-J., Firestone, R., Braggio, E., Asmann, Y., et al. (2026) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 18